AbbVie Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
AbbVie Inc. (ABBV) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of -$3.90 billion for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2026-08-03
- AbbVie Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2026-06-30 was -$1.52B.
- AbbVie Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2026-03-31 was -$2.39B.
- AbbVie Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-12-31 was -$1.41B.
- AbbVie Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-09-30 was -$776.00M.
- AbbVie Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2025 was -$6.50B.
- AbbVie Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2024 was -$3.77B.
- AbbVie Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2023 was -$5.13B.
- AbbVie Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2022 was -$2.76B.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month as first filed | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month as first filed | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month as first filed | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$1.52B derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$3.90B 10-Q · filed 2026-08-03 | -$5.31B derived: sum of 3 quarters · filed 2026-08-03 | -$6.09B derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2026-03-31 | -$2.39B 10-Q · filed 2026-05-08 | -$3.79B derived: sum of 2 quarters · filed 2026-05-08 | -$4.57B derived: sum of 3 quarters · filed 2026-05-08 | -$7.36B derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2025-12-31 | -$1.41B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | -$2.18B derived: sum of 2 quarters · filed 2026-02-20 | -$4.98B derived: sum of 3 quarters · filed 2026-08-03 | -$6.50B 10-K · filed 2026-02-20 | ||||
| 2025-09-30 | -$776.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$3.57B derived: sum of 2 quarters · filed 2026-08-03 | -$5.09B 10-Q · filed 2025-11-04 | -$5.37B derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2025-06-30 | -$2.79B derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$4.31B 10-Q · filed 2026-08-03 | -$4.59B derived: sum of 3 quarters · filed 2026-08-03 | -$5.95B derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2025-03-31 | -$1.52B 10-Q · filed 2026-05-08 | -$1.80B derived: sum of 2 quarters · filed 2026-05-08 | -$3.15B derived: sum of 3 quarters · filed 2026-05-08 | -$4.63B derived: sum of 4 quarters · filed 2026-05-08 | ||||
| 2024-12-31 | -$279.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | -$1.64B derived: sum of 2 quarters · filed 2026-02-20 | -$3.11B derived: sum of 3 quarters · filed 2026-02-20 | -$3.77B 10-K · filed 2026-02-20 | ||||
| 2024-09-30 | -$1.36B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$2.83B derived: sum of 2 quarters · filed 2025-11-04 | -$3.49B 10-Q · filed 2025-11-04 | -$5.19B derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2024-06-30 | -$1.48B derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | -$2.14B 10-Q · filed 2025-08-04 | -$3.83B derived: sum of 3 quarters · filed 2026-02-20 | -$3.84B derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2024-03-31 | -$660.00M 10-Q · filed 2025-05-09 | -$2.36B derived: sum of 2 quarters · filed 2026-02-20 | -$2.36B derived: sum of 3 quarters · filed 2026-02-20 | -$3.92B derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2023-12-31 | -$1.70B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | -$1.70B derived: sum of 2 quarters · filed 2026-02-20 | -$3.26B derived: sum of 3 quarters · filed 2026-02-20 | -$5.13B 10-K · filed 2026-02-20 | ||||
| 2023-09-30 | -$8.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | -$1.56B derived: sum of 2 quarters · filed 2024-11-04 | -$3.43B 10-Q · filed 2024-11-04 | -$5.55B derived: sum of 4 quarters · filed 2025-02-14 | ||||
| 2023-06-30 | -$1.55B derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$3.42B 10-Q · filed 2024-08-07 | -$5.54B derived: sum of 3 quarters · filed 2025-02-14 | -$5.32B derived: sum of 4 quarters · filed 2025-02-14 | ||||
| 2023-03-31 | -$1.87B 10-Q · filed 2024-05-03 | -$3.99B derived: sum of 2 quarters · filed 2025-02-14 | -$3.77B derived: sum of 3 quarters · filed 2025-02-14 | -$5.38B derived: sum of 4 quarters · filed 2025-02-14 | ||||
| 2022-12-31 | -$2.11B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | -$1.90B derived: sum of 2 quarters · filed 2025-02-14 | -$3.51B derived: sum of 3 quarters · filed 2025-02-14 | -$2.76B 10-K · filed 2025-02-14 | ||||
| 2022-09-30 | $214.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$1.40B derived: sum of 2 quarters · filed 2023-11-06 | -$647.00M 10-Q · filed 2023-11-06 | -$879.00M derived: sum of 4 quarters · filed 2024-02-20 | ||||
| 2022-06-30 | -$1.61B derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$861.00M 10-Q · filed 2023-08-07 | -$1.09B derived: sum of 3 quarters · filed 2024-02-20 | -$1.19B derived: sum of 4 quarters · filed 2024-02-20 | ||||
| 2022-03-31 | $748.00M 10-Q · filed 2023-05-05 | $516.00M derived: sum of 2 quarters · filed 2024-02-20 | $418.00M derived: sum of 3 quarters · filed 2024-02-20 | -$2.27B derived: sum of 4 quarters · filed 2024-02-20 | ||||
| 2021-12-31 | -$232.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | -$330.00M derived: sum of 2 quarters · filed 2024-02-20 | -$3.02B derived: sum of 3 quarters · filed 2024-02-20 | -$2.68B 10-K · filed 2024-02-20 | ||||
| 2021-09-30 | -$98.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | -$2.79B derived: sum of 2 quarters · filed 2022-11-04 | -$2.45B 10-Q · filed 2022-11-04 | -$7.12B derived: sum of 4 quarters · filed 2023-02-17 | ||||
| 2021-06-30 | -$2.69B derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$2.35B 10-Q · filed 2022-08-04 | -$7.02B derived: sum of 3 quarters · filed 2023-02-17 | -$7.22B derived: sum of 4 quarters · filed 2023-02-17 | ||||
| 2021-03-31 | $343.00M 10-Q · filed 2022-05-06 | -$4.33B derived: sum of 2 quarters · filed 2023-02-17 | -$4.53B derived: sum of 3 quarters · filed 2023-02-17 | -$5.34B derived: sum of 4 quarters · filed 2023-02-17 | ||||
| 2020-12-31 | -$4.67B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | -$4.87B derived: sum of 2 quarters · filed 2023-02-17 | -$5.68B derived: sum of 3 quarters · filed 2023-02-17 | -$5.75B 10-K · filed 2023-02-17 | ||||
| 2020-09-30 | -$197.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | -$1.01B derived: sum of 2 quarters · filed 2021-11-02 | -$1.08B 10-Q · filed 2021-11-02 | -$1.52B derived: sum of 4 quarters · filed 2022-02-18 | ||||
| 2020-06-30 | -$809.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-02 | -$881.00M 10-Q · filed 2021-08-02 | -$1.32B derived: sum of 3 quarters · filed 2022-02-18 | -$1.50B derived: sum of 4 quarters · filed 2022-02-18 | ||||
| 2020-03-31 | -$72.00M 10-Q · filed 2021-05-07 | -$510.00M derived: sum of 2 quarters · filed 2022-02-18 | -$690.00M derived: sum of 3 quarters · filed 2022-02-18 | -$2.99B derived: sum of 4 quarters · filed 2022-02-18 | ||||
| 2019-12-31 | -$438.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | -$618.00M derived: sum of 2 quarters · filed 2022-02-18 | -$2.92B derived: sum of 3 quarters · filed 2022-02-18 | -$3.09B 10-K · filed 2022-02-18 | ||||
| 2019-09-30 | -$180.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | -$2.48B derived: sum of 2 quarters · filed 2020-11-04 | -$2.65B 10-Q · filed 2020-11-04 | -$2.27B derived: sum of 4 quarters · filed 2021-02-19 | ||||
| 2019-06-30 | -$2.30B derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04 | -$2.47B 10-Q · filed 2020-08-04 | $2.47B 10-Q · filed 2019-08-05 | -$2.09B derived: sum of 3 quarters · filed 2021-02-19 | -$2.86B derived: sum of 4 quarters · filed 2021-02-19 | |||
| 2019-03-31 | -$169.00M 10-Q · filed 2020-05-08 | $169.00M 10-Q · filed 2019-05-03 | $214.00M derived: sum of 2 quarters · filed 2021-02-19 | -$555.00M derived: sum of 3 quarters · filed 2021-02-19 | -$70.00M derived: sum of 4 quarters · filed 2021-02-19 | |||
| 2018-12-31 | $383.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-19 | -$386.00M derived: sum of 2 quarters · filed 2021-02-19 | $99.00M derived: sum of 3 quarters · filed 2021-02-19 | -$49.00M 10-K · filed 2021-02-19 | $49.00M 10-K · filed 2019-02-27 | |||
| 2018-09-30 | -$769.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | -$284.00M derived: sum of 2 quarters · filed 2019-11-06 | -$432.00M 10-Q · filed 2019-11-06 | $432.00M 10-Q · filed 2018-11-07 | -$1.60B derived: sum of 4 quarters · filed 2020-02-21 | |||
| 2018-06-30 | $485.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | $337.00M 10-Q · filed 2019-08-05 | -$836.00M derived: sum of 3 quarters · filed 2020-02-21 | |||||
| 2018-03-31 | -$148.00M 10-Q · filed 2019-05-03 | -$1.32B derived: sum of 2 quarters · filed 2020-02-21 | ||||||
| 2017-12-31 | -$1.17B derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | -$626.00M 10-K · filed 2020-02-21 | $626.00M 10-K · filed 2019-02-27 | |||||
| 2017-09-30 | $547.00M 10-Q · filed 2018-11-07 | |||||||
| 2016-12-31 | $228.00M 10-K · filed 2019-02-27 | |||||||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-20 | $0.00 derived: sum of 2 quarters · filed 2015-02-20 | $0.00 derived: sum of 3 quarters · filed 2015-02-20 | -$1.00M 10-K · filed 2015-02-20 | ||||
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | $0.00 derived: sum of 2 quarters · filed 2014-11-07 | -$1.00M 10-Q · filed 2014-11-07 | $4.00M derived: sum of 4 quarters · filed 2015-02-20 | ||||
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | -$1.00M 10-Q · filed 2014-08-07 | $4.00M derived: sum of 3 quarters · filed 2015-02-20 | $11.00M derived: sum of 4 quarters · filed 2015-02-20 | ||||
| 2014-03-31 | -$1.00M 10-Q · filed 2014-05-09 | $4.00M derived: sum of 2 quarters · filed 2015-02-20 | $11.00M derived: sum of 3 quarters · filed 2015-02-20 | $13.00M derived: sum of 4 quarters · filed 2015-02-20 | ||||
| 2013-12-31 | $5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-20 | $12.00M derived: sum of 2 quarters · filed 2015-02-20 | $14.00M derived: sum of 3 quarters · filed 2015-02-20 | $17.00M 10-K · filed 2015-02-20 | ||||
| 2013-09-30 | $7.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $9.00M derived: sum of 2 quarters · filed 2013-11-12 | $12.00M 10-Q · filed 2013-11-12 | |||||
| 2013-06-30 | $2.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | $5.00M 10-Q · filed 2013-08-09 | ||||||
| 2013-03-31 | $3.00M 10-Q · filed 2013-05-08 | |||||||
| 2012-12-31 | $29.00M 10-K · filed 2014-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |